Trial
NCT03059446
Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Tobira Therapeutics, Inc.
Collaborators
—
Condition
Nonalcoholic Steatohepatitis
Intervention
Cenicriviroc
Why stopped
This study was terminated early due to lack of efficacy based on the results of Part I of the AURORA study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-02